Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Thu, 09.11.2023
bet-at-home.com AG
Mixed Q3 // High marketing spending to boost topline; chg
Yesterday, bet-at-home reported mixed Q3 results with a slightly weaker
than expected topline, but lower OPEX. In detail:
Sales came in at € 10.3m (-17% yoy, -6% qoq), slightly below our estimates
of € 10.9m, mainly due to lower betting GGR (€ 9.6m vs eNuW: € 10.0m) [ … ]
Thu, 09.11.2023
Deutsche Rohstoff AG
First Berlin Equity Research has published a research update on Deutsche
Rohstoff AG (ISIN: DE000A0XYG76). Analyst Simon Scholes reiterated his BUY
rating and decreased the price target from EUR 50.00 to EUR 47.00.
Abstract:
New wells helped DRAG post record sales and EBITDA numbers in Q3/23. While
we expect 2023 investment of €182m to exc [ … ]
Thu, 09.11.2023
Health Italia S.p.A.
Good first half-year. The focus on the core business model is paying off.
Forecast confirmed.
In the first half of 2023, revenues amounted to €17.81 million, signaling a
slight 7.5% decline compared to the same period in the previous year of
€19.25 million. This decline is primarily associated with the impact of the
'discontinued [ … ]
Thu, 09.11.2023
Knaus Tabbert AG
First Berlin Equity Research hat ein Research Update zu Knaus Tabbert AG
(ISIN: DE000A2YN504) veröffentlicht. Analyst Ellis Acklin bestätigt seine
BUY-Empfehlung und bestätigt sein Kursziel von EUR 86,00.
Zusammenfassung:
Der Q3-Bericht entsprach unseren Prognosen und übertraf die Vorjahreszahlen
bei weitem. Wie erwartet, gi [ … ]
Tue, 07.11.2023
Deutsche Effecten- und Wechsel- Beteiligungsgesellschaft AG
First Berlin Equity Research has published a research update on Deutsche
Effecten- und Wechsel- Beteiligungsgesellschaft AG (ISIN: DE0008041005).
Analyst Christian Orquera reiterated his BUY rating and maintained his EUR
1.80 price target.
Abstract:
DEWB has published its financial statement for H1/23. Overall results were
roughly as expected. [ … ]
Fri, 03.11.2023
Cenit AG
9 months 2023: Three more companies acquired in 2023; High revenue and
earnings growth achieved; Slight forecast and price target adjustment;
Rating: BUY
In the third quarter of 2023, CENIT AG achieved sales growth of 9.3% to €
45.84 million (Q3 2022: € 41.95 million), thus seamlessly continuing the
previous development of the cu [ … ]
Thu, 02.11.2023
Vectron Systems AG
acardo acquisition and digitisation strategy have positive influence; risk
from purchase price payment practically non-existent
After the fiscalisation effect has largely expired, Vectron Systems AG is
currently in a transformation process. Their focus is on the expansion of
digital services, so that in future the predominant part of Vectr [ … ]
Wed, 01.11.2023
Ikonisys SA
Strategic alliance with Biocare Medical is a game changer
Ikonisys announced that it has entered a strategic partnership with Biocare
Medical which will take advantage of each firm’s respective strengths to
drive and deepen their leading-edge technology positions. Ikonisys, in
addition, will substantially expand its global footprint [ … ]
Tue, 31.10.2023
PSI AG
First Berlin Equity Research has published a research update on PSI SE
(ISIN: DE000A0Z1JH9). Analyst Simon Scholes reiterated his BUY rating and
decreased the price target from EUR 32.00 to EUR 30.00.
Abstract:
PSI's order intake climbed 25.5% to €69m (Q3/22: €55m) in Q3/23 and was up
16.1% at €238m (9M/22: €205m) after nine [ … ]
Wed, 25.10.2023
Deutsche Rohstoff AG
First Berlin Equity Research has published a research update on Deutsche
Rohstoff AG (ISIN: DE000A0XYG76). Analyst Simon Scholes reiterated his BUY
rating and increased the price target from EUR 44.00 to EUR 50.00.
Abstract:
DRAG has raised base-case revenue and EBITDA guidance for 2023 by 20.6% and
16.7% respectively and for 2024 by 11.1% and [ … ]